The U.S. government limited Medicare coverage of Biogen Inc.¡¯s Alzheimer¡¯s disease treatment and similar drugs to patients enrolled in clinical trials, a highly unusual move that will curb access to the controversial treatment approved last year.
Coverage of Biogen¡¯s therapy, sold under the brand name Aduhelm, and other amyloid-targeted Alzheimer¡¯s therapies, will be limited to people participating in qualified clinical trials, the Centers for Medicare & Medicaid Services (CMS) said in a statement Tuesday.
The decision is preliminary and will be followed by a 30-day public comment period. A final determination is due in April. The policy will set national rules for how Medicare treats Aduhelm and similar drugs that may follow.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.